← Back to Search

Monoclonal Antibodies

Imsidolimab low dose for Pustular Psoriasis (GEMINI1 Trial)

Phase 3
Waitlist Available
Research Sponsored by AnaptysBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4
Awards & highlights
Pivotal Trial

Summary

This trial is testing a new medication called imsidolimab to help adults with a severe skin condition known as generalized pustular psoriasis. The medication aims to reduce inflammation and skin pustules by calming the immune system. Researchers are also studying how the body processes the medication and its potential side effects.

Eligible Conditions
  • Generalized Pustular Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: IV low dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody Low Dose
Group II: IV high dose Imsidolimab, other name ANB019Experimental Treatment1 Intervention
ANB019 Biological Humanized Monoclonal Antibody High Dose
Group III: IV PlaceboPlacebo Group1 Intervention
Placebo Solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Imsidolimab
Not yet FDA approved
Imsidolimab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

AnaptysBio, Inc.Lead Sponsor
16 Previous Clinical Trials
1,603 Total Patients Enrolled
Bruce Randazzo, MDStudy DirectorAnaptysBio, Inc.
10 Previous Clinical Trials
774 Total Patients Enrolled

Media Library

Imsidolimab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05352893 — Phase 3
Pustular Psoriasis Research Study Groups: IV Placebo, IV high dose Imsidolimab, other name ANB019, IV low dose Imsidolimab, other name ANB019
Pustular Psoriasis Clinical Trial 2023: Imsidolimab Highlights & Side Effects. Trial Name: NCT05352893 — Phase 3
Imsidolimab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05352893 — Phase 3
~13 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top